Nasdaq GlobeNewswire

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC

Del

InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro.

Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs.  The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC. 

Anti-fibrotic therapies aim to inhibit activation of hepatic stellate cell (HSCs), thereby preventing excessive accumulation of extracellular matrix (ECM) proteins, such as collagen, which can lead to cirrhosis and liver failure.  The InSphero 3D InSight(TM) Human Liver Fibrosis Model is unique in that it contains all liver cell types necessary to mimic fibrosis in vitro in a high throughput, screening-compatible platform.  

InSphero Chief Scientific Officer Dr. Patrick Guye says, "Our 3D human fibrosis model is composed of primary human liver cells, including HSCs, hepatocytes, Kupffer cells, and liver endothelial cells, all of which are required to accurately reflect the clinical fibrotic disease state in a cell culture model. Treatment of the model with TGF-b1, a known inducer of HSC activation, was shown to trigger strong induction of pro-fibrotic gene expression and ECM protein accumulation in the microtissue, resulting in collagen deposition and diminished hepatocyte function, both hallmarks of liver fibrosis. Even more promising, we were clearly able to demonstrate successful inhibition of disease progression on a phenotypic and transcriptional level using drugs known to interfere with pro-fibrotic signalling pathways." 

Dr. Jan Lichtenberg, InSphero Chief Executive Officer and Co-founder, notes, "These findings support the power of our model to help drug discovery groups meet the demand for safer, more effective anti-fibrotic drugs. The initial feedback from beta testers within major pharmaceutical groups with fibrosis programs has been overwhelmingly positive.  Not only does the model overcome the lack of cellular complexity of current in vitro models, but being based on our pharma-validated Human Liver Microtissue platform, it can deliver valuable data on both the efficacy and safety of drug candidates, without the use of animal models."  

AASLD Presentation Details
Friday, October 20: 12:00 - 1:30 PM
Abstract #385: Development and characterization of a novel in vitro human liver fibrosis model for efficacy testing of anti-fibrotic drugs based on 3D Human Liver Microtissues
Poster presented by: Dr. Radina Kostadinova, InSphero AG

For more information about InSphero, visit www.insphero.com.

###

InSphero contacts 

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
randy.strube@insphero.com

Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
jan.lichtenberg@insphero.com

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight(TM) Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology. All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight(TM) solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Switzerland, with subsidiaries in the United States and Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and LinkedIn.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1201e5f9-a462-4dca-b453-e61881c14090

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/63584ccd-618f-48fd-aec4-5e289e46c2de

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c0354196-0927-49f8-9fb5-2a57e0e2d025

Randy Strube
InSphero AG
800-619-6800
randy.strube@insphero.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InSphero AG via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Track Your PR Results With Tribe Builder Media’s New Analytics Software23.10.2018 23:15Pressemelding

Tribe Builder Media now provides its clients with comprehensive AI and data-science backed tools to leverage publicity and build business. New York, NY, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Danielle Sabrina, founder of Tribe Builder Media and one of CIO’s 2018 Female Entrepreneurs to Follow, has announced the rollout of the company’s comprehensive analytics software -- taking this proven results-driven media agency to the next level. With team members coming from backgrounds in journalism, linguistics and digital marketing, Tribe Builder Media has over a 90% success rate getting clients featured in top-tier publications. They develop top-notch thought leadership and provide insight beyond best-guess metrics like ad equivalency and reach/readership to prove tangible impact. The agency’s foundation of artificial intelligence and machine learning offers infinite ways to segment, break down, and compare coverage exactly how clients need it in real time. Tribe Builder Media’s new software feat

Glatfelter’s Composite Fibers Business Unit Announces 7% Price Increase23.10.2018 16:37Pressemelding

GERNSBACH, Germany, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Glatfelter (NYSE: GLT) announced today its Composite Fibers Business Unit will increase prices by 7% for all its products, effective November 19, 2018. The decision is a direct result of substantial and ongoing global price increases for key raw materials including pulp, synthetic fibers, viscose and other chemicals. Furthermore, the Company does not see any near-term relief from this input cost inflation. Escalating energy and transportation costs further compound the inflationary situation. “Glatfelter has made extensive efforts to reduce costs and increase efficiency,” said Martin Rapp, Senior Vice President and Business Unit President, Composite Fibers. “However, these initiatives alone are not enough to offset the impact of the external pressures. Therefore, we are implementing price adjustments to ensure our continued ability to supply best-in-class products, innovation and service.” About Glatfelter Glatfelter is a leading gl

Elite Capital & Co. Limited Awarded the “Best Project Management & Finance Company UK 2108” by Global Banking & Finance Review23.10.2018 16:10Pressemelding

LONDON, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Mr. George Matharu, President of Elite Capital & Co. Limited (ECC), announced today that the success of being in the Global Banking & Finance Review Magazine’s 2018 Awards List was the result of enormous effort and teamwork within the company since it was founded in 2012. These Awards were established to reward excellence and recognize best practice and innovation across the Worldwide business community. Global Banking & Finance Review celebrate those who have attained the peak of achievement in terms of distinction and market influence. The list mirrors the nominations, suggestions and contributions of the readership and analyses new trends to uncover the best and the brightest pioneers in business today. This is recognition of ECC’s drive to design solutions for clients after they have exhausted traditional funding sources and methods. Elite Capital & Co. Limited is a private limited company that provides project related services including Ma

Aryaka Announces Expanded Cloud Offerings with Oracle FastConnect23.10.2018 15:00Pressemelding

Global enterprises can combine fast deployment, application performance, and security in a fully-managed service with direct connections to Oracle Cloud Infrastructure SAN MATEO, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Aryaka®, a leading global SD-WAN provider and Silver level member of Oracle PartnerNetwork (OPN), today announced it will offer dedicated and private access to the Oracle Cloud through Oracle Cloud Infrastructure FastConnect. With Aryaka’s SD-WAN as a Service and Oracle Cloud Infrastructure FastConnect, enterprises can now access their applications in the Oracle Cloud through private connections facilitated by Aryaka. Using Aryaka’s software-defined private network results in higher reliability, faster application performance, lower latencies, and higher security than typical connections over MPLS or the public Internet. Support for Oracle Cloud Infrastructure FastConnect is an integral part of Aryaka’s SD-WAN for Multi-Cloud solution which allows customers to connect

Compuware and CollabNet VersionOne Announce Integration of ISPW and Continuum23.10.2018 15:00Pressemelding

Partnership Enables Value Stream Management with Unified View of Cross-Platform Development and Deployment Application Development and Delivery Professionals are under pressure to track the progress of code deliverables across the DevOps lifecycle based on their value to the business. Large enterprises are additionally seeking increased visibility and control over agile development work across all platforms—from inception to delivery. The integration of ISPW, Compuware’s DevOps-enabled source code management solution for the mainframe, and CollabNet VersionOne’s Continuum release delivery platform, will serve this customer need. LAS VEGAS, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Compuware and CollabNet VersionOne today announced the completed integration of their respective products, ISPW and Continuum. The companies previously announced they were partnering to help large enterprises unify their Value Stream Management (VSM) by incorporating their critical mainframe software development acti

Hitachi Vantara Completes REAN Cloud Acquisition23.10.2018 15:00Pressemelding

Deal Strengthens Hitachi Vantara’s Ability To Accelerate Customers’ Digital Transformation Journeys SANTA CLARA, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE: 6501), today announced the completion of its acquisition of REAN Cloud LLC, a global cloud systems integrator, managed services provider and solutions developer of cloud-native applications across big data, machine learning and emerging internet of things (IoT) spaces. Through this acquisition, Hitachi Vantara gains critical capabilities and industry-leading expertise in cloud migration and modernization, instantly elevating its cloud offering portfolio and managed services capabilities. Directly complementing the strength of its Hitachi Enterprise Cloud (HEC) and on-premises deployments, Hitachi Vantara’s solutions offer unified cloud management for workloads across public, private and hybrid cloud environments. By combining REAN Cloud’s expertise in public cloud and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom